このアイテムのアクセス数: 140

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s41467-023-44266-z.pdf3.41 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorMaeda, Raeen
dc.contributor.authorSeki, Natsumien
dc.contributor.authorUwamino, Yoshifumien
dc.contributor.authorWakui, Masatoshien
dc.contributor.authorNakagama, Yuen
dc.contributor.authorKido, Yasutoshien
dc.contributor.authorSasai, Miwaen
dc.contributor.authorTaira, Shuen
dc.contributor.authorToriu, Naoyaen
dc.contributor.authorYamamoto, Masahiroen
dc.contributor.authorMatsuura, Yoshiharuen
dc.contributor.authorUchiyama, Junen
dc.contributor.authorYamaguchi, Genkien
dc.contributor.authorHirakawa, Makotoen
dc.contributor.authorKim, Yun-Gien
dc.contributor.authorMishima, Masayoen
dc.contributor.authorYanagita, Motokoen
dc.contributor.authorSuematsu, Makotoen
dc.contributor.authorSugiura, Yukien
dc.contributor.alternative前田, 黎ja
dc.contributor.alternative関, 夏実ja
dc.contributor.alternative上蓑, 義典ja
dc.contributor.alternative涌井, 昌俊ja
dc.contributor.alternative中釜, 悠ja
dc.contributor.alternative城戸, 康年ja
dc.contributor.alternative笹井, 美和ja
dc.contributor.alternative平, 修ja
dc.contributor.alternative鳥生, 直哉ja
dc.contributor.alternative山本, 雅裕ja
dc.contributor.alternative松浦, 善治ja
dc.contributor.alternative内山, 純ja
dc.contributor.alternative山口, 元輝ja
dc.contributor.alternative平川, 真実ja
dc.contributor.alternative金, 倫基ja
dc.contributor.alternative三島, 眞代ja
dc.contributor.alternative柳田, 素子ja
dc.contributor.alternative末松, 誠ja
dc.contributor.alternative杉浦, 悠毅ja
dc.date.accessioned2024-01-18T02:36:46Z-
dc.date.available2024-01-18T02:36:46Z-
dc.date.issued2023-12-20-
dc.identifier.urihttp://hdl.handle.net/2433/286640-
dc.descriptionCOVID-19が重症化する人は血液の代謝産物組成が異なる --感染初期での重症化リスクの予測マーカーを同定--. 京都大学プレスリリース. 2024-01-16.ja
dc.description.abstractEffective early-stage markers for predicting which patients are at risk of developing SARS-CoV-2 infection have not been fully investigated. Here, we performed comprehensive serum metabolome analysis of a total of 83 patients from two cohorts to determine that the acceleration of amino acid catabolism within 5 days from disease onset correlated with future disease severity. Increased levels of de-aminated amino acid catabolites involved in the de novo nucleotide synthesis pathway were identified as early prognostic markers that correlated with the initial viral load. We further employed mice models of SARS-CoV2-MA10 and influenza infection to demonstrate that such de-amination of amino acids and de novo synthesis of nucleotides were associated with the abnormal proliferation of airway and vascular tissue cells in the lungs during the early stages of infection. Consequently, it can be concluded that lung parenchymal tissue remodeling in the early stages of respiratory viral infections induces systemic metabolic remodeling and that the associated key amino acid catabolites are valid predictors for excessive inflammatory response in later disease stages.en
dc.language.isoeng-
dc.publisherSpringer Natureen
dc.rights© The Author(s) 2023en
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.subjectCytokinesen
dc.subjectMetabolomicsen
dc.subjectSARS-CoV-2en
dc.titleAmino acid catabolite markers for early prognostication of pneumonia in patients with COVID-19en
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleNature Communicationsen
dc.identifier.volume14-
dc.relation.doi10.1038/s41467-023-44266-z-
dc.textversionpublisher-
dc.identifier.artnum8469-
dc.addressCenter for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicineen
dc.addressCenter for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicineen
dc.addressDepartment of Laboratory Medicine, Keio University School of Medicine; Department of Infectious Diseases, Keio University School of Medicineen
dc.addressDepartment of Laboratory Medicine, Keio University School of Medicineen
dc.addressDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan Universityen
dc.addressDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan Universityen
dc.addressResearch Institute for Microbial Diseases, Osaka University; Center for Infectious Disease Education and Research, Osaka Universityen
dc.addressFaculty of Food and Agricultural Sciences, Fukushima Universityen
dc.addressDepartment of Nephrology, Graduate School of Medicine, Kyoto University; Institute for the Advanced Study of Human Biology (ASHBi), Kyoto Universityen
dc.addressResearch Institute for Microbial Diseases, Osaka University; Center for Infectious Disease Education and Research, Osaka Universityen
dc.addressResearch Institute for Microbial Diseases, Osaka University; Center for Infectious Disease Education and Research, Osaka Universityen
dc.addressResearch Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio Universityen
dc.addressResearch Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio Universityen
dc.addressResearch Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio Universityen
dc.addressResearch Center for Drug Discovery, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio Universityen
dc.addressDepartment of Biochemistry, Keio University School of Medicineen
dc.addressDepartment of Nephrology, Graduate School of Medicine, Kyoto University; Institute for the Advanced Study of Human Biology (ASHBi), Kyoto Universityen
dc.addressDepartment of Biochemistry, Keio University School of Medicine; WPI-Bio2Q Research Center, Keio University, and Central Institute for Experimental Medicine and Life Scienceen
dc.addressCenter for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine; Department of Biochemistry, Keio University School of Medicineen
dc.identifier.pmid38123556-
dc.relation.urlhttps://www.kyoto-u.ac.jp/ja/research-news/2024-01-16-0-
dcterms.accessRightsopen access-
datacite.awardNumber22K15927-
datacite.awardNumber22H02833-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22K15927/-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22H02833/-
dc.identifier.eissn2041-1723-
jpcoar.funderName日本学術振興会ja
jpcoar.funderName日本学術振興会ja
jpcoar.awardTitle抗体アビディティ --成熟を指標としたSARS-CoV-2防御免疫のレジリエンス評価ja
jpcoar.awardTitleCOVID-19重症化を特徴付ける早期免疫代謝の解明と予後マーカーの探索ja
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons